GSK vaccine shortages

Hepatyrix protects against hepatitis A and typhoid | SCIENCE PHOTO LIBRARY
Hepatyrix protects against hepatitis A and typhoid | SCIENCE PHOTO LIBRARY

GlaxoSmithKline has warned of impending shortages of two of its vaccines.

Owing to a delay in the start-up of a new manufacturing plant, capacity normally reserved for producing typhoid antigen for Typherix and Hepatyrix has been switched to the production of critical childhood vaccines. This situation is expected to last until the end of 2013. Current stocks of Typherix are believed to have been exhausted, but supplies of Hepatyrix are expected to last until the end of the year.

Alternative hepatitis A vaccines are available from GSK, Sanofi Pasteur MSD or Crucell while typhoid vaccines are available from Sanofi Pasteur MSD or Crucell.

Vaccine Update– August/September 2011

Updated 1 March 2013


Hepatyrix doses released

A consignment of 300,000 doses of Hepatyrix has been made available for use in the UK. It is anticipated that this stock will sell out during May 2013. No further doses are subsequently expected to be made available until the last quarter of 2014.


Vaccine Update - January 2013

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more